Disease landscape

Lung Cancer clinical trials

Get alerts when Lung Cancer trials change

3,202 active trials 1,792 recruiting 360 Phase 3 1,120 sponsors 439 changes in 30 days

Data updated daily from ClinicalTrials.gov, last refresh 2026-09-05

What changed in the last 30 days showing 49 of 439 changes on 20 trials

2026-09-04
Trial terminated
Trial terminated: Operational challenges
Final enrollment: 2 participants — 5% of the 40 planned
Primary completion confirmed: July 2026 (last estimated August 2028)
NCT06405230 Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular… · GlaxoSmithKline · Phase 1/2
2026-08-14
Trial terminated
Trial terminated: Following completion of Phase 1b, the Sponsor decided not to initiate Part 2 of the trial.
Primary endpoint(s) modified
Primary completion moved earlier: 2025-07 → 2025-04-30
Completion moved earlier: 2025-11 → 2025-04-30
NCT05572684 A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants… · NextCure, Inc. · Phase 1/2
2026-09-03
Reclassified as terminated (was completed)
Trial terminated: Study closed by Amgen due to lack of enrollment
NCT06333678 A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer… · Memorial Sloan Kettering Cancer Center · Phase 2
2026-08-28
Withdrawn before enrolling
Trial withdrawn: Other - Protocol moved to Withdrawn
Enrollment reduced: 24 → 0 participants
NCT06982222 Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have… · National Cancer Institute (NCI) · Phase 1
2026-08-29
Trial status changed: Not Yet Recruiting → Suspended
Recruitment suspended: Administrative
NCT07639242 Olomorasib + Pembrolizumab KRAS G12C Mutant, PD-L1 TPS 1-49% Locally Advanced or… · UNC Lineberger Comprehensive Cancer Center · Phase 2
2026-08-15
Recruitment suspended
Recruitment suspended: Placed on voluntary hold to new recruitment pending modification to combination monoclonal antibody treatment.
NCT06694454 Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab… · National Cancer Institute (NCI) · Phase 1/2
2026-08-14
Trial status changed: Completed → Terminated
Trial terminated: Accrual and drug manufacturing and supply were discontinued in 2025.
NCT02769962 Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With… · National Cancer Institute (NCI) · Phase 1/2
2026-09-04
Primary completion pushed: 2026-10-31 → 2027-06-30
Trial sites reduced: 164 → 161 locations
Completion pushed: 2026-10-31 → 2027-06-30
NCT03178552 A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments… · Hoffmann-La Roche · Phase 2/3
2026-09-05
Primary completion pushed: 2025-12-09 → 2027-06
Recruitment opened
Completion pushed: 2026-04-03 → 2027-12
NCT06641609 A Phase I Study of CFT8919 in Patients With Advanced NSCLC · Betta Pharmaceuticals Co., Ltd. · Phase 1
2026-09-04
Primary completion pushed: 2026-04 → 2026-12
Enrollment closed, study ongoing
Completion pushed: 2026-04 → 2026-12
NCT06337084 Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors · Monopar Therapeutics · Phase 1
2026-09-03
Primary completion pushed: 2026-03 → 2027-03
Completion pushed: 2026-03 → 2027-03
NCT03893955 A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy… · AbbVie · Phase 1
2026-09-03
Primary completion pushed: 2026-12-31 → 2027-12-31
Completion pushed: 2027-01-29 → 2028-01-29
NCT06049212 Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in… · Merck Sharp & Dohme LLC · Phase 1
2026-09-02
Primary completion pushed: 2027-01-01 → 2028-01-01
Completion pushed: 2027-01-01 → 2028-01-01
NCT03401385 First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01) · Daiichi Sankyo Co., Ltd. · Phase 1
2026-09-03
Primary completion pushed: 2026-07-31 → 2026-11-12
Completion pushed: 2026-07-31 → 2026-11-12
NCT07413757 CHOICE:Decision Factor of EGFR-TKI in Chinese IV NSCLC · AstraZeneca
2026-08-29
Primary completion pushed: 2026-12-30 → 2027-10-30
Enrollment increased: 190 → 300 participants
Completion pushed: 2028-07-30 → 2028-12-30
NCT06813365 Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR… · Dizal Pharmaceuticals · Phase 1
2026-08-29
Primary completion pushed: 2035-01-31 → 2039-04-01
Completion pushed: 2035-01-31 → 2039-04-01
NCT06096844 Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With… · National Cancer Institute (NCI) · Phase 3
2026-08-14
Primary completion pushed: 2026-01 → 2026-12
NCT04853342 To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With… · Allist Pharmaceuticals, Inc. · Phase 3
2026-08-14
Primary completion pushed: 2026-09-30 → 2029-09-30
Completion pushed: 2027-02-28 → 2030-08
NCT06416410 JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced… · Allist Pharmaceuticals, Inc. · Phase 3
2026-09-04
Primary completion pushed: 2026-07 → 2027-01
Completion pushed: 2026-11 → 2027-04
NCT04699838 Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients… · Muhammad Furqan · Phase 2
2026-09-04
Primary completion pushed: 2026-09-30 → 2029-09-30
Completion pushed: 2026-09-30 → 2029-09-30
NCT04892953 Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage… · M.D. Anderson Cancer Center · Phase 2

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-09-02 NCT07799194 For Patients With Early-Stage Non-Small Cell Lung Cancer or Lung Oligo-metastatic Tumor… Energenx Medical LTD. new
2026-09-01 NCT07798362 Iriscope for the Diagnosis of Peripheral Pulmonary Lesions: a Multicentre Randomised… Erasme University Hospital new
2026-08-31 NCT07795580 The Effects of Low-Intensity Endurance Exercise on Improving Fatigue, Sleep, Quality of… Taipei Medical University new
2026-08-27 NCT07791147 Family-centred Pulmonary Rehabilitation to Empower Carers Aveiro University new
2026-08-26 NCT07786909 ERICA-02 Study : Impact of Physical Exercise on the Tumor Immune Microenvironment in… Centre Leon Berard new
2026-08-26 NCT07788729 Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their… University of Regensburg new
2026-08-25 NCT07785791 ERAS Compliance and Nutritional Outcomes After Lung Cancer Surgery Bursa City Hospital new
2026-08-25 NCT07783971 Study on the Microbial Environment of Non-small Cell Lung Cancer Based on Mycogenomics… 958th Army Hospital of the Chinese People's Liberation Army new
2026-08-24 NCT07781852 Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and… Lumina Pharmaceuticals Inc new Early Phase 1
2026-08-19 NCT07772895 Pemefolacianine for IMI of Lung Cancer Sunil Singhal new Phase 1

Active trials by phase

Early Phase 1
32
Phase 1
403
Phase 1/2
307
Phase 2
796
Phase 2/3
47
Phase 3
313
Phase 4
33
Not charted: 1,271 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Active trials top 25 of 3,202

NCT IDTitleSponsorStatusUpdated
Phase 4
NCT03340506 Dabrafenib and/or Trametinib Rollover Study Novartis Pharmaceuticals Recruiting 2026-09-04
NCT07761351 A Randomized Controlled Trial Comparing Percutaneous CT-Guided Biopsy and Shape-Sensing… Intuitive Surgical Recruiting 2026-09-02
NCT07279935 Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… AstraZeneca Recruiting 2026-08-27
NCT06908070 Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab Idris Bahce Recruiting 2026-08-20
NCT07704658 Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors Rigel Pharmaceuticals Recruiting 2026-08-10
NCT07754812 Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… Shanghai Pulmonary Hospital, Shanghai, China Recruiting 2026-08-10
NCT07744698 Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… Anhui Provincial Cancer Hospital Recruiting 2026-08-04
NCT07405086 Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… OHSU Knight Cancer Institute Recruiting 2026-06-12
NCT06646471 PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With… GFPC Investigation Recruiting 2026-04-29
NCT06330038 Anesthesia and Non-small Cell Lung Cancer Recurrence Samsung Medical Center Recruiting 2026-04-20
NCT06105801 EBUS-TBNA vs Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation… Vanderbilt-Ingram Cancer Center Recruiting 2026-02-02
NCT07320105 Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy… Fujian Cancer Hospital Recruiting 2026-01-06
NCT05874401 Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)… Pharmacosmos A/S Recruiting 2025-09-04
NCT05463913 Lung Nodule Detection Using Ultra-long FOV PET/CT University Medical Center Groningen Recruiting 2025-03-07
NCT05748093 Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With… Maastricht University Medical Center Recruiting 2024-08-09
NCT06467786 Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer Tang-Du Hospital Recruiting 2024-06-21
NCT05525338 Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib… University Medical Center Groningen Recruiting 2024-05-13
NCT05663242 The Effects of Using Different Anesthetics on the Prognosis of Primary Lung Tumors and… Kaohsiung Medical University Chung-Ho Memorial Hospital Recruiting 2023-05-30
NCT05172739 Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in… University of Crete Recruiting 2021-12-29
NCT07802847 Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and… Gustave Roussy, Cancer Campus, Grand Paris Not Yet Recruiting 2026-09-03
NCT07768358 Tucatinib Continuation Study Pfizer Not Yet Recruiting 2026-08-28
NCT05144997 Lorlatinib Continuation Study Pfizer Active, Not Recruiting 2026-08-26
NCT07674368 Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed Hunan Cancer Hospital Not Yet Recruiting 2026-07-01
NCT07671560 Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant… Qiming Wang Not Yet Recruiting 2026-06-26
NCT07633613 Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor… Centre Antoine Lacassagne Not Yet Recruiting 2026-06-08
See all 3,202 active Lung Cancer trials with filters →

Top sponsors by active trials in this area

AstraZeneca (81) · M.D. Anderson Cancer Center (58) · National Cancer Institute (NCI) (57) · Shanghai Pulmonary Hospital, Shanghai, China (55) · Memorial Sloan Kettering Cancer Center (45) · Shanghai Chest Hospital (44) · Sun Yat-sen University (42) · Fudan University (33) · Hunan Province Tumor Hospital (30) · Merck Sharp & Dohme LLC (30)

Get alerts when Lung Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free